Clinical Nephrology, Volume 57 (2002) - February (95 - 107)

Lupus nephritis: a clinical review for practicing nephrologists
G. Contreras, D. Roth, V. Pardo, L.G. Striker, D.R. Schultz
1 Dialysis Unit VAMC, 2 Division of Nephrology, 3 Electron Microscopy VAMC, 4 Renal Cell Biology Laboratory and 5 Division of Rheumatology and Immunology, Veterans Affairs Medical Center and University of Miami School of Medicine, Miami, FL, USA

   

 

DOI 10.5414/CNP57095

Abstract

The renal manifestations in systemic lupus erythematosus (SLE) are protean and difficult to categorize into clinical syndromes and histologic classes. Lupus nephritis is frequently unrecognized until full-blown nephritic and/or nephrotic syndrome with renal failure emerge. Epidemiologically, approximately one third of SLE patients from unselected populations have renal involvement early during the disease. Most renal abnormalities emerge within the first few years of SLE diagnosis. Currently, most nephrologists agree that an early renal biopsy is worthwhile in those SLE patients with abnormal urinalysis and/or reduced renal function. First, it provides a histologic categorization of the glomerulonephritis as well as an assessment of the degree of activity and chronicity. Second, it provides vital prognostic information. Third, it is beneficial in planning a more rational therapy with or without potentially toxic immunosuppressive agents. Over the last 3 decades, many controlled clinical trials for treatment of lupus nephritis have been completed with a few therapeutic immunosuppressive regimens. Among those agents used, cyclophosphamide and azathioprine provide a reduction of morbidity in those patients afflicted with proliferative forms of lupus glomerulonephritis. A new immunosuppressive agent, mycophenolate mofetil, is being studied for treatment of proliferative forms of lupus glomerulonephritis in a controlled clinical trial at our institution. Immunosuppressive agents and the availability of dialysis and transplantation have improved the survival of patients with lupus nephritis, in particular those with proliferative forms.

Author Details

Authors

Departments

  • 1 Dialysis Unit VAMC,
  • 2 Division of Nephrology,
  • 3 Electron Microscopy VAMC,
  • 4 Renal Cell Biology Laboratory and
  • 5 Division of Rheumatology and Immunology, Veterans Affairs Medical Center and University of Miami School of Medicine, Miami, FL, USA

Address

Citation

G. Contreras, D. Roth, V. Pardo, L.G. Striker and D.R. Schultz.Lupus nephritis: a clinical review for practicing nephrologists. 2002; 57: 95-107. doi: 10.5414/CNP57095.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart